RESOURCES FOR HEALTHCARE PROFESSIONALS
Below you will find a range of resources to help you successfully integrate APRETUDE into your clinic, and equip you with the knowledge to feel confident discussing APRETUDE for pre-exposure prophylaxis (PrEP) with people in your care.
To view or download resources, please click the links below.
Administration Video
Correct preparation and administration is important, we are here to help you. Watch this video to learn more.
Information on who could benefit from APRETUDE, how to initiate and dose correctly, storage and handling, and information to support the use of APRETUDE in your practice.
Information for nurses on APRETUDE dosing and administration, user support including pre- and post-injection considerations, storage and FAQs
References:
- APRETUDE (cabotegravir) 600 mg suspension for injection Summary of Product Characteristics (SmPC)
- New cabotegravir formulations approved to help prevent HIV-1 infection in adults and adolescents, GOV.UK. Available at: https://www.gov.uk/government/news/new-cabotegravir-formulations-approved-to-help-prevent-hiv-1-infection-in-adults-and-adolescents. Accessed January 2025.
PM-GB-CBT-WCNT-240007 April 2025
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
